不同类型白血病的化学治疗是以白血病细胞对抗癌药物的选择性敏感作用为基础的.然而,在治疗过程中,白血病患者常常对原先敏感的某种药物产生抵抗性.事实上,患者在疗程中的某个阶段常常会对长春新碱(VCR)和脱氢皮质醇(Prednisolone)产生抵抗性.本研究旨在于投用VCR 后用阿糖胞苷(Ara-C)来克服急性淋巴母细胞白血病(acutelymphoblastic leukemia)中的药物抵抗性.作 Chemotherapy for different types of leukemia is based on the selective sensitivity of leukemia cells to anticancer drugs. However, during treatment, leukemia patients are often resistant to a drug that was previously sensitive. In fact, the patient is on course In some stages, resistance to vincristine (VCR) and Prednisolone often occurs. The aim of this study was to use cytarabine (Ara-C) to overcome acute lymphoblasts after administration of VCR. Drug Resistance in Acutely Mphoblastic Leukemia.